CDKN2A and cancer: Based on the data of MSK-IMPACT (a cancer genome study done at Memorial Sloan Kettering Cancer Center), the European Society for Medical Oncology (ESMO) reported that the germline conversion rate of CDKN2A variants was limited, at 4.3% (29/676), and that the characteristic finding of germline CDKN2A variant carriers was an early tumor onset (< 30 years of age) [24].